**High trader confidence in "No" (96%) for a new coronavirus pandemic in 2026 stems from sustained low-level circulation of SARS-CoV-2 and absence of any novel coronavirus with pandemic potential.** As of mid-August 2026, CDC data show COVID-19 infections growing modestly across U.S. states with reproductive number estimates around 1.08, yet emergency department visits remain very low at 0.3% and hospitalizations/deaths continue declining globally per WHO reporting. A mild summer wave is underway but produces far fewer severe outcomes than prior years, consistent with endemic management rather than escalation. No official alerts from WHO, CDC, or ECDC indicate emergence of a new coronavirus strain capable of widespread human-to-human transmission with high virulence or immune escape that would trigger pandemic criteria. Surveillance systems strengthened after 2020 have improved early detection of zoonotic threats, and no concerning signals—such as clusters of severe respiratory illness linked to animal reservoirs—have materialized in 2026. Hypothetical risks from viruses like canine coronavirus or influenza D remain speculative in the literature without observed spillover events meeting pandemic thresholds. Realistic scenarios that could still shift outcomes before year-end include an undetected zoonotic spillover of a novel coronavirus achieving efficient airborne transmission or rapid evolution of SARS-CoV-2 into a more severe variant, though current genomic and epidemiological monitoring make these low-probability events in the remaining months. Market-implied odds reflect aggregated trader assessment of these low baseline risks and lack of triggering developments.